Aggressive Breast Cancer Diagnosis May Be Thwarted By Vitamin D Receptor Protein

Article

Researchers found that expression of the vitamin D receptor protein may help protect against aggressive forms of breast cancer.

Researchers found that expression of the vitamin D receptor (VDR) protein may help protect against aggressive forms of breast cancer. The study was first published online in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR).

“A complex interplay exists among vitamin D, hormone receptors and the development and progression of breast cancer cells,” says the study’s senior author, Song Yao, PhD, Associate Professor of Oncology in the Department of Cancer Prevention and Control at Roswell Park, in a news release. “This study offers new and valuable insights into the mechanisms of vitamin D and the influence this important micronutrient has on aggressive breast cancer subtypes.”

VDR expression in breast tumors was determined by examining 1,114 female patients using immunohistochemistry (IHC) and looking for low, moderate, and strong expression. The results showed that 58% of breast tumors had moderate or strong VDR expression. VDR expression was inversely related to aggressive tumor characteristics, including large tumor size, hormonal receptor (HR) negativity, and triple-negative subtype (P < .05). VDR expression was also inversely related to Ki-67 expression among patients older than 50 years.

Although this finding has not yet been linked to improved patient survival, this is promising for follow-up studies.

“We speculate that the tumor vitamin D receptor levels might change throughout the course of the disease, are modified by circulating vitamin D levels, or are subject to molecular controls by vitamin D, genetic variations and other factors. Further studies are needed to elucidate the mechanisms impacting the regulation of vitamin D receptor expression in breast tumors,” said Yao.

This may leave people wondering about vitamin D supplementation via sunlight or vitamins as a prevention strategy. The National Cancer Institute notes that incidence and death rates for certain cancers are shown to be lower among people living in southern latitudes, where levels of sunlight exposure are relatively high compared to those living in northern latitudes, and so researchers hypothesized that variation in vitamin D levels might account for this association. However, additional research based on stronger study designs will help to determine whether higher vitamin D levels are related to lower cancer incidence or death rates.

 

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.